Listeriolysin O |
|
Vaxjo ID |
405 |
|
Vaccine Adjuvant Name |
Listeriolysin O |
|
Alternative Names |
Listeriolysin O is sometimes abbreviated as LLO. |
|
Adjuvant VO ID |
VO_0005687
|
|
Description |
Listeriolysin O is a pore-forming toxin produced by Listeria monocytogenes. It is known for its immunogenic properties and ability to enhance immune responses when used as an adjuvant in vaccines. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Listeriolysin O (LLO) of Listeria monocytogenes is a toxin with an extremely immunogenic feature |
|
Structure |
Listeriolysin O is a protein that forms oligomeric structures and contains several functional domains that contribute to its immunogenicity and cytotoxicity. |
|
Preparation |
Listeriolysin O is prepared through genetic engineering and expression in suitable systems, such as bacterial cultures. |
|
Dosage |
In the study, Listeriolysin O was administered at a dose of 10 ug when co-administered with the NS3 DNA vaccine. |
|
Function |
The findings may have important implication for LLO gene application as genetic adjuvant in immune response against HCV. |
|
Safety |
The article indicates that Listeriolysin O has been shown to enhance immune responses without significant toxicity when used in appropriate doses. |
| References |
Pouriayevali et al., 2019: Pouriayevali MH, Bamdad T, Sadat SM, Sadeghi SA, Sabahi F, Mahdavi M, Aghasadeghi MR. Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. IUBMB life. 2019; 71(10); 1645-1652. [PubMed: 31298809].
|
